Skip to search formSkip to main contentSkip to account menu

BZL101

Known as: Apoptosis Inducer BZL101 
An orally active aqueous extract derived from the plant Scutellaria barbata with potential antineoplastic activity. Sparing normal cells, apoptosis… 
National Institutes of Health

Related topics

Related topics

2 relations
Positive Regulation of Apoptosis

Broader (1)

Scutellaria barbata extract

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer
The purpose of this study was to determine the safety and maximum tolerated dose (MTD) of BZL101 (FDA IND# 59,521), an orally… 
Highly Cited
2010
Highly Cited
2010
BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype
BZL101 is an aqueous extract from the Scutellaria barbata plant shown to have anticancer properties in a variety of human cancers… 
2010
2010
Abstract ES9-2: Understanding the Role of Botanicals in the Management of Breast Cancer
Botanical agents have been used for centuries based on empiric observations of salutary effects on a variety of illnesses. A… 
2008
2008
Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata, towards breast cancer cells
We studied the mechanism of the cytotoxic activity of BZL101, an aqueous extract from the herb Scutellaria barbata D. Don, which… 
2008
2008
A phase I trial of scutellaria barbata (BZL101) for metastatic breast cancer
1099 Background: BZL101 is an aqueous extract from herba Scutellaria Barbata. BZL101 demonstrates in vitro growth inhibitory… 
2007
2007
Molecular mechanisms underlying selective cytotoxic activity of BZL101, an extract of Scutellaria barbata D. Don, towards breast cancer cells
C59 BZL101, an aqueous extract from the herb Scutellaria barbata D. Don, has completed a phase I clinical trial in a heavily… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)